Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all?

被引：19

作者：

Goicoechea, Miguel

Best, Brookie

机构：

[1] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA

[2] Antiviral Res Ctr, San Diego, CA 92103 USA

[3] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, San Diego, CA 92103 USA

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2007年 / 8卷 / 03期

关键词：

efavirenz; emtricitabine; fixed-dose combination; HIV; tenofovir;

D O I：

10.1517/14656566.8.3.371

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

ATRIPLA(TM) (Bristol-Myers Squibb and Gilead Sciences) is a complete regimen in a single, fixed-dose combination tablet that contains: efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg. Current treatment guidelines recommend this triple combination for initial therapy because of its excellent potency, tolerability and favorable safety profile. individually, these agents have long half-lifes that allow for once-daily dosing and may provide a pharmacologic bridge for the occasional missed dose. Although several options for once-daily regimens are available, comparative clinical trials are still in progress. This article reviews relevant efficacy and safety data of efavirenz, emtricitabine and tenofovir disoproxil fumarate, compared with other once-daily agents or certain common alternate drugs presently used as initial therapy in treatment-naive patients.

引用

收藏

页码：371 / 382

页数：12

相关论文

共 86 条

[61] Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors [J].

Piliero, PJ .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2004, 37 :S2-S12

[62]

Podzomczer D, 2005, ANTIVIR THER, V10, P171

[63]

Pozniak AL, 2006, JAIDS-J ACQ IMM DEF, V43, P535

[64] Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients [J].

Pruvost, A ;

Negredo, E ;

Benech, H ;

Theodoro, F ;

Puig, J ;

Grau, E ;

García, E ;

Moltó, J ;

Grassi, J ;

Clotet, B .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (05) :1907-1914

[65] Mechanism of active renal tubular efflux of tenofovir [J].

Ray, Adrian S. ;

Cihlar, Tomas ;

Robinson, Kelly L. ;

Tong, Leah ;

Vela, Jennifer E. ;

Fuller, Michael D. ;

Wieman, Lani M. ;

Eisenberg, Eugene J. ;

Rhodes, Gerry R. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (10) :3297-3304

[66] Greater and more rapid depletion of mitochondrial DNA in blood of patients treated with dual (zidovudine plus didanosine or zidovudine plus zalcitabine) vs. single (zidovudine) nucleoside reverse transcriptase inhibitors [J].

Reiss, P ;

Casula, M ;

de Ronde, A ;

Weverling, GJ ;

Goudsmit, J ;

Lange, JMA .

HIV MEDICINE, 2004, 5 (01) :11-14

[67] Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: An adult AIDS clinical trials group study [J].

Ribaudo, HJ ;

Haas, DW ;

Tierney, C ;

Kim, RB ;

Wilkinson, GR ;

Gulick, RM ;

Clifford, DB ;

Marzolini, C ;

Fletcher, CV ;

Tashima, KT ;

Kuritzkes, DR ;

Acosta, EP .

CLINICAL INFECTIOUS DISEASES, 2006, 42 (03) :401-407

[68]

RIDDLER SA, 2006, 16 INT AIDS C TOR CA

[69] Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), bis(isopropyloxymethylcarbonyl)PMPA [J].

Robbins, BL ;

Srinivas, RV ;

Kim, C ;

Bischofberger, N ;

Fridland, A .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (03) :612-617

[70] Efficacy and safety of emtricitabine vs stavudine in combination therapy in anti retroviral-naive patients - A randomized trial [J].

Saag, MS ;

Cahn, P ;

Raffi, F ;

Wolff, M ;

Pearce, D ;

Molina, JM ;

Powderly, W ;

Shaw, AL ;

Mondou, E ;

Hinkle, J ;

Borroto-Esoda, K ;

Quinn, JB ;

Barry, DW ;

Rousseau, F .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (02) :180-190

← 1 2 3 4 5 6 7 8 9 →